JPRN-jRCT2080223608已完成1 期
A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination with Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab,BMS-734016) in Advanced and/or Metastatic Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participants must have histologic or cytologic confirmation of a solid malignancy that is advanced (metastatic and/or unresectable)
- •Presence of at least 1 lesion with measurable disease as defined by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria for response assessment
- •The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Other protocol defined inclusion/exclusion criteria could apply
排除标准
- •Participants with untreated central nervous system (CNS) metastases
- •Participants with an active, known, or suspected autoimmune disease
- •Uncontrolled or significant cardiovascular disease
- •Other protocol defined inclusion/exclusion criteria could apply
研究者
相似试验
进行中（未招募）
1 期
Study of the Safety and Pharmacokinetics of Venetoclax in Children and Young Adults with Relapsed or Refractory MalignanciesEUCTR2017-000439-14-FRAbbVie Deutschland GmbH & Co. KG135
已完成
不适用
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancieson-Hodgkin lymfomen, neuroblastoom en overige solide tumorenAML/ALL/NHL/NeuroblastomaPediatric cancer10024324NL-OMON50736AbbVie B.V.4
进行中（未招募）
1 期
Study of the Safety and Pharmacokinetics of Venetoclax in Children and Young Adults with Relapsed or Refractory MalignanciesIn Part 1 patients with any relapsed or refractory tumor will be eligible to enroll. During Part 2 patients with the following malignancies: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), or neuroblastoma are eligle to enroll. In addition patients with any tumor that expresses BCL-2 can also enrol.EUCTR2017-000439-14-NLAbbVie Deutschland GmbH & Co. KG135
进行中（未招募）
1 期
Study of the Safety and Pharmacokinetics of Venetoclax in Children and Young Adults with Relapsed or Refractory MalignanciesEUCTR2017-000439-14-GBAbbVie Deutschland GmbH & Co. KG145
进行中（未招募）
1 期
Study of the Safety and Pharmacokinetics of Venetoclax in Children and Young Adults with Relapsed or Refractory MalignanciesEUCTR2017-000439-14-DEAbbVie Deutschland GmbH & Co. KG140